financetom
Business
financetom
/
Business
/
Origin Bancorp Q2 Earnings, Revenue Fall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Origin Bancorp Q2 Earnings, Revenue Fall
Jul 23, 2025 3:16 PM

05:58 PM EDT, 07/23/2025 (MT Newswires) -- Origin Bancorp ( OBK ) reported Q2 earnings late Wednesday of $0.47 per diluted share, down from $0.67 a year earlier.

Analysts polled by FactSet expected $0.78 per share.

Adjusted total revenue for the quarter ended June 30 was $72.6 million, down from $85.4 million a year earlier.

Analysts surveyed by FactSet expected $97.6 million, if comparable.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rare Earth Stocks Rise Pre-Bell After China Tightens Export Controls
Rare Earth Stocks Rise Pre-Bell After China Tightens Export Controls
Oct 9, 2025
08:20 AM EDT, 10/09/2025 (MT Newswires) -- Rare earth stocks, including MP Materials ( MP ) , Energy Fuels ( UUUU ) , and NioCorp Developments ( NB ) , were up premarket Thursday after China's Ministry of Commerce said it established new export controls on rare earth-related technologies. New regulations prohibit the export of technologies used to mine and...
Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients
Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients
Oct 9, 2025
08:19 AM EDT, 10/09/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) said Thursday its partner SQ Innovation received US Food and Drug Administration approval for Lasix Onyu, an at-home furosemide treatment for edema in adults with chronic heart failure that can be injected under the skin. The drug-device uses a high-concentration furosemide delivered via a small Infusor with a...
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study
Oct 9, 2025
08:19 AM EDT, 10/09/2025 (MT Newswires) -- Alterity Therapeutics ( ATHE ) said Thursday that data from a 77-patient phase 2 clinical trial of its drug ATH434 for the potential treatment of multiple system atrophy slowed disease progression. Chief Executive David Stamler said the ongoing double-blind trial showed a stabilization of orthostatic hypotension, a symptom of multiple system atrophy, at...
MAC Copper Says UK Court Approves Harmony Gold Mining Acquisition
MAC Copper Says UK Court Approves Harmony Gold Mining Acquisition
Oct 9, 2025
08:21 AM EDT, 10/09/2025 (MT Newswires) -- MAC Copper ( MTAL ) said Thursday that the Royal Court of Jersey has approved Harmony Gold Mining's ( HMY ) proposed acquisition of the company. MAC Copper ( MTAL ) said it will submit a copy of the court's orders with the Jersey Registrar of Companies on Friday to make the deal...
Copyright 2023-2026 - www.financetom.com All Rights Reserved